Lexaria Bioscience Corp. to Present at H.C. Wainwright Global Investment Conference
News provided byLexaria Bioscience Corp · 1 min read
Kelowna, British Columbia, Lexaria Bioscience Corp. (NASDAQ: LEXX), a global leader in oral drug delivery platforms, will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place from September 14 to 16, 2026, in New York City.
CEO Richard Christopher will present the company’s latest developments and be available for one-on-one meetings with investors throughout the conference. The presentation will be accessible online via this link.
The H.C. Wainwright Global Investment Conference is a prominent platform for biotechnology and pharmaceutical companies to showcase their advancements and engage with potential investors. Lexaria Bioscience Corp. will leverage this opportunity to discuss its innovative DehydraTECH™ technology, which has demonstrated the ability to enhance drug bio-absorption and deliver drugs more effectively across the blood-brain barrier.
DehydraTECH™, Lexaria’s proprietary drug delivery platform, represents a significant advancement in oral drug delivery systems. The technology has been granted 66 patents and is in the process of securing additional patents worldwide. Lexaria operates a licensed research laboratory and maintains a robust intellectual property portfolio, positioning it as a key player in the biotech industry.
“Lexaria Bioscience Corp. is excited to participate in this year’s H.C. Wainwright Global Investment Conference,” said Richard Christopher, CEO of Lexaria Bioscience Corp. “This event provides an excellent platform to share the progress and potential of our DehydraTECH™ technology with a broader audience of investors and industry peers.”
The conference will offer an opportunity for Lexaria to highlight its ongoing research and development initiatives, as well as its strategic partnerships and future growth prospects. The company’s management team will address topics such as the clinical applications of DehydraTECH™, its potential benefits in improving drug efficacy, and the company’s plans for expanding its market reach.
Lexaria Bioscience Corp. continues to invest in its technology and aims to bring new and improved drug delivery solutions to market. The company’s presence at the conference underscores its commitment to advancing oral drug delivery systems and delivering value to its shareholders.